# Prognostic Value of Protein IMP3 Expression in Cervical Cancer

> **NCT05151159** · — · COMPLETED · sponsor: **University of Mostar** · enrollment: 80 (actual)

## Conditions studied

- Cervical Carcinoma

## Interventions

- **OTHER:** immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3

## Key facts

- **NCT ID:** NCT05151159
- **Lead sponsor:** University of Mostar
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01-01
- **Primary completion:** 2013-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05151159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05151159, "Prognostic Value of Protein IMP3 Expression in Cervical Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05151159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*